Neurogenic progression may falter in MDD
Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.
-
By
-
Andrea Surnit
-
August 26, 2026
-
Clinical Scorecard: Neurogenic progression may falter in MDD
At a Glance
| Category | Detail |
|---|
| Condition | Major Depressive Disorder (MDD) |
| Key Mechanisms | Disrupted adult hippocampal neurogenesis and stalled progression from neural stem-like cells to neuroblasts. |
| Target Population | Patients with major depressive disorder without recent psychotropic medication use. |
| Care Setting | Postmortem analysis of hippocampal tissue. |
Key Highlights
- Patients with MDD showed impaired neurogenic progression.
- Fewer neuroblasts and more quiescent neural stem cells were observed in MDD patients.
- Molecular alterations included increased expression of interferon-related genes and SOX9 in intermediate neural progenitors.
- Proteomic profiling identified 297 differentially expressed proteins in MDD.
- Changes extended beyond neurogenic populations affecting neurotransmission and neuroinflammation.
Guideline-Based Recommendations
Diagnosis
- Postmortem analysis of hippocampal tissue to assess neurogenic changes.
Management
- Consideration of molecular alterations in neurogenic progression when treating MDD.
Monitoring & Follow-up
- Assessment of neurogenic lineage progression in patients with MDD.
Risks
- Limitations in distinguishing MDD-related pathology from suicide-related pathology.
Patient & Prescribing Data
Patients with MDD without comorbid substance or alcohol use disorders.
No psychotropic medication use within 3 months prior to death except benzodiazepines.
Clinical Best Practices
- Utilize multiomic analyses to understand neurogenic progression in MDD.
- Monitor for molecular alterations in hippocampal circuitry in MDD patients.
Related Resources & Content
